Aromatase inhibitor-related musculoskeletal syndrome (AIMSS) is a significant adverse effect of prolonged endocrine therapy in early breast cancer patients, stemming from estrogen deprivation. This evidence concerns the gene CYP19A1 and breast carcinoma.